Quetiapine as Prophylaxis for Delirium in CABG

• Status: Recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

low-dose quetiapine may be effective in preventing delirium in patients. The purpose of this study is to evaluate the efficacy and safety of quetiapine for delirium prophylaxis in cabg

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ain Shams University
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

Patients aged 65 or older old of age undergoing open heart surgery and having an equal or greater score of 5 on the scale of Delphi.

• Age: 70-79 years: 1 point; ≥ 80 years: 2 points

• Physical activity: need for assistance, not self-sufficient: 2 points

• Alcoholism: 1 point

• Hearing impaired: 1 point

• History of delirium: 2 points

• Emergency of surgery: 2 points

• No laparoscopic surgery: 2 points

• Admission critical unites: 3 points

• Value of C reactive protein (CRP) ≥ 10mg/dl: 1 point

Exclusion Criteria:

.Patient refusal.

• Allergy to quetiapine

• Patients with a score less than 5 on Delphi scale

• Diagnosis of delirium on admission initial CAM-ICU (the Confusion Assessment Method-ICU) positive)

• Could not communicate due to previously diagnosed irreversible neurologic disease (stroke, cerebral hemorrhage, traumatic brain injury, dementia, etc.)

• High risk for ventricular arrhythmias (Corrected QT interval ≥ 460 millisecond in men, ≥ 470 millisecond in women or ongoing treatment with drugs known to prolong the QT interval (e.g., erythromycin, class Ia, Ic, III anti-arrhythmic drugs)

• Second or third degree heart block

• High risk for drug interaction with quetiapine (phenytoin, carbamazepine, barbiturates)

• Electrolyte disturbance : Potassium less than 3 or magnesium less than 1.5

• Patient on antipsychotic drug treatment prior to admission

• Parkinson's disease